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Abstract
Background: Recent literature suggests a role for apolipo-
protein L (apoL) aberrations in the pathogenesis of schizo-
phrenia. ApoL is almost exclusively associated with
apolipoprotein A-I in high-density lipoproteins (HDLs). The
objective of this study was to examine the correlation
between symptom scores and serum HDL in antipsychotic-
naive schizophrenia patients.
Methods: In this cross-sectional study, 60 antipsychotic-
naive schizophrenia patients were systematically examined
for their symptom scores, with good inter-rater reliability.
Concurrently, an overnight fasting serum lipid profile from
these patients was assessed.
Results: Serum HDL had a significant inverse correlation
with a total negative syndrome score (rs–0.43; ps0.001).
Conclusions: The study observation supports the potential
role for HDL abnormalities in the genesis of negative symp-
toms in schizophrenia.
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Introduction
Lipid abnormalities have been hypothesized to play a central
role in the pathogenesis of schizophrenia (1–3). Apolipopro-
tein L (apoL) is a 42-kDa plasma apolipoprotein that has
four forms of apoL, namely apoL I–IV, which are encoded
by separate genes on chromosome 22 (4). ApoL-I is
expressed ubiquitously in the central nervous system, and
robust up-regulation of the APOL-I gene has been demon-
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strated in the prefrontal cortex of patients with schizophrenia
(5).
ApoL is almost exclusively associated with apoA-I in
high-density lipoproteins (HDLs) (6). Interestingly, HDLs
have been demonstrated to have an adaptive influence on
certain brain structures such as the hippocampus (7). Indeed,
various lines of evidence support the possibility of a signal-
ling exchange between peripheral and brain lipids (7). Thus,
assessment of serum lipids might potentially indicate the
status of lipids in the brain lipid. Indeed, such relationships
have been demonstrated in studies examining patients with
dementia (8).
HDL is intricately associated with the prefrontal cortex,
because of its link with apoL, and can adaptively influence
the hippocampus. Also important, prefrontal (9) as well as
hippocampal (10) abnormalities have consistently been dem-
onstrated in patients with schizophrenia. In addition, these
structural abnormalities of the brain have been linked to the
positive and negative syndrome of schizophrenia (9–11).
Since peripheral and brain lipids have signalling exchange
between them (7), it is possible that serum HDL might show
an association with symptom scores in patients with
schizophrenia.
To the best of our knowledge, the symptom correlate of
serum HDL in antipsychotic-naive schizophrenia patients has
not been examined. The objective of this study was to eval-
uate an association between symptom scores and serum HDL
in antipsychotic-naive patients with schizophrenia.
Materials and methods
Patients were recruited from individuals attending the clinical serv-
ices of the National Institute of Mental Health and Neurosciences
(India) and who fulfilled DSM-IV (Diagnostic and Statistical Man-
ual of Mental Disorders) criteria for schizophrenia. Patients that
were never treated with any psychotropic medication, including
antipsychotics, and did not have substance abuse, were referred by
the screening clinical psychiatrist for participation in the study. The
patients were recruited over a period of 15 months, from September
2007 to November 2008. The diagnosis of schizophrenia was estab-
lished by a qualified psychiatrist using Mini International Neuro-
psychiatric Interview Plus (12). The diagnosis was confirmed by
another psychiatrist through an independent clinical interview. The
details related to onset of illness and antipsychotic-naive status were
ascertained with reliable information obtained from at least two
adult relatives.
Psychosis symptoms were assessed using the Scale for Assess-
ment of Positive Symptoms (SAPS) (13) and the Scale for Assess-
ment of Negative Symptoms (SANS) (14). The SAPS total score
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was calculated by adding the following sub-scores: hallucinations,
delusions, bizarre behavior, and formal thought disorder. The SANS
total score was calculated by adding the following sub-scores: affec-
tive flattening, alogia, avolition-apathy, anhedonia-asociality and
attention impairments. All the patients were rated by RA who had
established a good inter-rater reliability (intra-class correlation coef-
ficient )0.9) with another trained rater by examining, in turn, 10
patients.
For all subjects, weight (kg) and height (m) were measured and
body mass index (BMI) (kg/m2) was calculated. The propensity to
develop diabetes mellitus was assessed in all subjects using the
Simplified Indian Diabetes Risk Score (SIDRS) (15). SIDRS is cal-
culated based on the following parameters that are recommended
by the American Diabetes Association: age, waist circumference,
family history of diabetes mellitus and physical activity. SIDRS is
a validated tool to assess the risk for developing diabetes mellitus
in an Indian population. Though SIDRS is yet to be validated in
people with mental illness, the simplicity of the questions as well
as the scoring system enabled us to use it with ease in patients with
schizophrenia (16). In addition, the information to calculate SIDRS
was obtained from at least two adult relatives of the patient to ensure
reliability. None of the subjects (patients and controls) had a family
history of diabetes in any of their first-degree relatives. All subjects
had a SIDRS of F50.
None of the patients had alcohol abuse/dependence. None used
stimulants or opiate drugs. None had history or clinical feature sug-
gestive of a neurological/medical disorder. None had abnormal
movements as assessed by Abnormal Involuntary Movements Scale
(17). Clinical assessments and collection of blood samples were
performed on the same day, before starting antipsychotics. Follow-
ing a complete description of the study to the subjects, written
informed consent was obtained. The Institute’s Ethics Committee
approved the study.
Blood samples were collected from all subjects between 0800 and
0900 h (A.M.) after 12 h overnight fast. Blood was collected from
an ante-cubital vein into vacutainer tubes (Becton and Dickinson,
Franklin Lakes, NJ, USA). After centrifugation of blood, serum was
used for biochemical analyses. Glucose, liver and renal function
tests, and serum lipid profiles were analyzed using the Olympus
AU400 analyzer (Olympus Europa GmbH, Hamburg, Germany).
Statistical analyses were performed using the Statistical Package for
Social Sciences (version-11) (SPSS Inc, Chicago, IL, USA). Spear-
man’s test and partial correlation analysis were used for correlation
analyses. The statistical significance was set at p-0.05 (two-tailed).
Results
The demographic characteristics of the patients were as
follows: age (mean"SD) – 29.9"7.4 years; gender ratio
(men:women) – 33:27. The Indian Diabetes Risk Score of
the patients was 38.0"15.6 and the BMI (kg/m2) was
18.6"3.5. The psychopathology scores were as follows:
SAPS total score – 28.4"15.1; SANS total score –
65.5"28.8. The fasting serum lipid profile was as follows:
HDL – 1.2"0.3 mmol/L; total cholesterol – 4.2"1.1
mmol/L; triglycerides – 1.1"0.6 mmol/L; very low-density
lipoprotein (VLDL) – 0.5"0.3 mmol/L. There was signifi-
cant negative correlation between SAPS and SANS total
scores (rs–0.64; p-0.001). Serum HDL showed a signif-
icant inverse correlation with SANS total score (rs–0.43;
ps0.001) (Figure 1). This correlation remained significant
even after correcting for the potential confounding influence
(if any) of SAPS total score (ps0.01). There was no signif-
icant correlation between serum HDL and the SAPS total
score. None of the other lipid parameters had any significant
correlation with the SAPS/SANS total scores.
Discussion
To the best of our knowledge, this is the first study to dem-
onstrate significant negative correlation between serum HDL
and a negative syndrome score in antipsychotic-naive
patients with schizophrenia. Both frontal and limbic deficits
underlie the negative syndrome in schizophrenia (9–11).
Interestingly, HDL can potentially influence both of these
regions of the brain (5, 7). Thus, our study observations are
consistent with current theories on genesis of symptoms in
patients with schizophrenia.
ApoL belongs to the HDL family that plays an important
role in cholesterol transport (6). The cholesterol content of
membranes is critical as it influences cellular processes by
modulating gene transcription and signal transduction, both
in the adult brain and during neurodevelopment (18). It is
important to note that robust up-regulation of the APOL-I
gene has been demonstrated in the prefrontal cortex of
patients with schizophrenia (5). Interestingly, the APOL
genes are clustered on chromosome 22q12 (5). Several
reports have shown this chromosomal region to be linked
with schizophrenia (19, 20). Another factor that makes this
chromosomal region critical is the fact that the velocardio-
facial syndrome (VCFS) has been linked to a region close
by on chromosome 22q11 (21, 22). A significant proportion
of patients with VCFS experience schizophrenia-like psy-
choses (21, 22). All these observations further strengthen the
possible link between serum HDL and the pathogenesis of
schizophrenia.
Some of the methodological strengths of this study include
examination of antipsychotic-naive patients with schizophre-
nia, rigorous procedures to establish the diagnosis, good
inter-rater reliability for assessment of symptoms, raters
being blinded to the study hypothesis and lipid parameters,
and stringent evaluation of patients to avoid potential con-
founding effects of other medical diseases on lipids. Some
of the potential study limitations include i) lack of concurrent
evaluation of brain morphometry in these patients which
might have ascertained further the influence of serum HDL
on negative syndrome, ii) assessment of the apoL moiety of
lipoproteins would have further elucidated the pathogenetic
mechanisms, and iii) lack of comprehensive evaluation of
the dietary pattern in patients with schizophrenia.
In summary, the results of this study suggest a significant
inverse relationship between serum HDL and the negative
syndrome in schizophrenia. Further studies are needed to
extend this finding by concurrent assessment of ApoL para-
meters as well as brain structure/function.
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Figure 1 Significant negative correlation between serum HDL and SANS total score in antipsychotic-naive patients with schizophrenia
(ns60).
To convert conventional HDL values to SI units, multiply with 0.02586.
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